Literature DB >> 7707089

Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.

C E Shaw1, P R Dunbar, H A Macaulay, T J Neale.   

Abstract

Magnetic resonance imaging of multiple sclerosis (MS) patients often shows active inflammatory lesions despite clinical remission. No immunological marker of disease activity has been identified in these patients. Concentrations of neopterin, interleukin-2 (IL-2), soluble interleukin-2 receptor (sIL-2R) and tumour necrosis factor-alpha (TNF-alpha) were measured in the serum and cerebrospinal fluid of 19 clinically-inactive MS patients and compared with those of 19 non-inflammatory controls. Cerebrospinal fluid (CSF) neopterin concentrations were significantly higher in the MS group than in controls (mean 9.1 mM vs 3.4 nM, P < 0.01) and 10 of 19 MS patients had levels above the control range. This finding provides evidence of ongoing T-cell-directed and interferon-gamma-mediated macrophage activation in the central nervous system. Analysis of IL-2, sIL-2R and TNF-alpha concentrations revealed no significant differences between MS patients and controls. We conclude that CSF neopterin concentration may correlate with disease activity in asymptomatic patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7707089     DOI: 10.1007/bf00887815

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  44 in total

1.  Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6.

Authors:  S L Hauser; T H Doolittle; R Lincoln; R H Brown; C A Dinarello
Journal:  Neurology       Date:  1990-11       Impact factor: 9.910

2.  Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis.

Authors:  K Adachi; T Kumamoto; S Araki
Journal:  Ann Neurol       Date:  1990-11       Impact factor: 10.422

3.  Prospective serial analysis of interleukin-2 and soluble interleukin-2 receptor in relapsing-remitting multiple sclerosis.

Authors:  M S Freedman; K L Muth; J L Trotter; C N Yoshizawa; J P Antel
Journal:  Neurology       Date:  1992-08       Impact factor: 9.910

4.  Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients.

Authors:  E W Willoughby; E Grochowski; D K Li; J Oger; L F Kastrukoff; D W Paty
Journal:  Ann Neurol       Date:  1989-01       Impact factor: 10.422

5.  CSF neopterin as marker of disease activity in multiple sclerosis.

Authors:  S Fredrikson; H Link; P Eneroth
Journal:  Acta Neurol Scand       Date:  1987-05       Impact factor: 3.209

Review 6.  The soluble interleukin-2 receptor: biology, function, and clinical application.

Authors:  L A Rubin; D L Nelson
Journal:  Ann Intern Med       Date:  1990-10-15       Impact factor: 25.391

7.  Tumor necrosis factor alpha (TNF alpha) and neurological diseases. Failure in detecting TNF alpha in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumours.

Authors:  P Gallo; M G Piccinno; L Krzalic; B Tavolato
Journal:  J Neuroimmunol       Date:  1989-06       Impact factor: 3.478

8.  Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosis.

Authors:  A Noronha; A Toscas; M A Jensen
Journal:  Ann Neurol       Date:  1992-01       Impact factor: 10.422

9.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.

Authors:  D H Miller; P Rudge; G Johnson; B E Kendall; D G Macmanus; I F Moseley; D Barnes; W I McDonald
Journal:  Brain       Date:  1988-08       Impact factor: 13.501

10.  Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.

Authors:  C Huber; J R Batchelor; D Fuchs; A Hausen; A Lang; D Niederwieser; G Reibnegger; P Swetly; J Troppmair; H Wachter
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Evaluating the safety profile of focused ultrasound and microbubble-mediated treatments to increase blood-brain barrier permeability.

Authors:  Dallan McMahon; Charissa Poon; Kullervo Hynynen
Journal:  Expert Opin Drug Deliv       Date:  2019-01-29       Impact factor: 6.648

2.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

Review 3.  Biomarkers in Multiple Sclerosis.

Authors:  Anu Paul; Manuel Comabella; Roopali Gandhi
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

4.  Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.

Authors:  Morten Stilund; Mikkel Carstensen Gjelstrup; Thor Petersen; Holger Jon Møller; Peter Vestergaard Rasmussen; Tove Christensen
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.